151 related articles for article (PubMed ID: 11756850)
1. Treat early, but treat hard: Interferon-beta dose makes a difference.
Mikol DD
J Neuroophthalmol; 2001 Dec; 21(4):237-9. PubMed ID: 11756850
[No Abstract] [Full Text] [Related]
2. [Interferon therapy of multiple sclerosis. A question of the correct dose?].
Hohlfeld R
Nervenarzt; 2001 Feb; 72(2):67-8. PubMed ID: 11256156
[No Abstract] [Full Text] [Related]
3. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
[No Abstract] [Full Text] [Related]
4. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
Chofflon M; Ben-Amor AF
Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
[No Abstract] [Full Text] [Related]
5. Multiple sclerosis and interferon beta-1b, past, present and future.
Horowski R
Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
[No Abstract] [Full Text] [Related]
6. Early treatment and dose optimisation BENEFIT and BEYOND.
Hartung HP
J Neurol; 2005 Sep; 252 Suppl 3():iii44-iii50. PubMed ID: 16170501
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of prolonged immunomodulatory treatment with interferon beta.
Demina TL; Khachanova NV; Davydovskaya MV; Popova NF; Gusev EI
Neurosci Behav Physiol; 2009 Jun; 39(5):497-9. PubMed ID: 19430980
[No Abstract] [Full Text] [Related]
8. Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?
Durelli L; Oggero A; Verdun E; Isoardo G; Ricci A; Barbero P; Bergamasco B
J Neurol Sci; 2000 Sep; 178(1):37-41. PubMed ID: 11018247
[TBL] [Abstract][Full Text] [Related]
9. The importance of maintaining effective therapy in multiple sclerosis.
Durelli L; Clerico M
J Neurol; 2005 Sep; 252 Suppl 3():iii38-iii43. PubMed ID: 16170500
[TBL] [Abstract][Full Text] [Related]
10. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
Benatar M
Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424021
[No Abstract] [Full Text] [Related]
11. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
Rice G
Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
[No Abstract] [Full Text] [Related]
12. Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.
Goodin DS
Drugs; 2001; 61(12):1693-703. PubMed ID: 11693459
[TBL] [Abstract][Full Text] [Related]
13. Editorial commentary to Narayanan et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.
Matthews PM
J Neurol; 2001 Nov; 248(11):987. PubMed ID: 11757964
[No Abstract] [Full Text] [Related]
14. Optimizing immunomodulatory therapy for MS patients: an integrated management model.
Jeffery D; Bashir K; Buchwald L; Coyle P; Freedman M; Markowitz C; Rammohan K; Reder T; Sharief M; Wolinsky J
J Neurol Sci; 2002 Sep; 201(1-2):89-90. PubMed ID: 12163200
[No Abstract] [Full Text] [Related]
15. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
[TBL] [Abstract][Full Text] [Related]
16. The REFLEX study: a missed opportunity?
Giovannoni G
Lancet Neurol; 2012 Jan; 11(1):22-4. PubMed ID: 22146410
[No Abstract] [Full Text] [Related]
17. Introduction.
Owens GM
J Manag Care Pharm; 2013; 19(1 Suppl A):S3. PubMed ID: 23383727
[No Abstract] [Full Text] [Related]
18. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?].
MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501
[No Abstract] [Full Text] [Related]
19. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
Frohman EM; Racke M; van Den Noort S
Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
[No Abstract] [Full Text] [Related]
20. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
